Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori ‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial
Abstract
Helicobacter pylori infection is linked to various gastrointestinal conditions, such as chronic active gastritis, peptic ulcers, and gastric cancer. Traditional treatment options encounter difficulties due to antibiotic resistance and adverse effects. Therefore, the aim of this study was to explore the effectiveness of a new treatment plan that combines vonoprazan (VPZ), amoxicillin, and bismuth for the eradication of H. pylori.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Contribution of social science to large scale biodiversity conservation: A review of research about the Natura 2000 network
- The alignment of agricultural and nature conservation policies in the European Union
- Determination of ecological significance based on geostatistical assessment: a case study from the Slovak Natura 2000 protected area
- Routledge Handbook of the Study of the Commons
- Farmers' acceptance of results-based agri-environmental schemes: A German perspective
- Approaches to Identify the Value of Seminatural Habitats for Conservation Biological Control
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.